Peter Faris

Peter Faris

Auto-generated profile, based on publicly available information

Peter Faris

Alberta Health Services, Calgary, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2018 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
CSCongshi Shi
Congshi Shi
PFPeter Faris
Peter Faris
DMDeborah A. McNeil
Deborah A. McNeil
SPSteven Patterson
Steven Patterson
MPMelissa L. Potestio
Melissa L. Potestio
LMLindsay McLaren
Lindsay McLaren
Although oral health has improved remarkably in recent decades, not all populations have benefited equally. Ethnic identity, and in particular visible minority status, has been identified as an important risk factor for poor oral health. Canadian research on ethnic disparities in oral health is extremely limited. The aim of this study was to examine ethnic disparities in oral health outcomes and to assess the extent to which ethnic disparities could be accounted for by demographic, socioeconomic and caries-related behavioral factors, among a population-based sample of grade 1 and 2 schoolchildren (age range: 5-8 years) in Alberta, Canada. A dental survey (administered during 2013-14) included a mouth examination and parent questionnaire. Oral health outcomes included: 1) percentage of children with dental caries; 2) number of decayed, extracted/missing (due to caries) and filled teeth; 3) percentage of children with two or more teeth with untreated caries; and 4) percentage of children with parental-ratings of fair or poor oral health. We used multivariable regression analysis to examine ethnic disparities in oral health, adjusting for demographic, socioeconomic and caries-related behavioral variables. We observed significant ethnic disparities in children’s oral health. Most visible minority groups, particularly Filipino and Arab, as well as Indigenous children, were more likely to have worse oral health than White populations. In particular, Filipino children had an almost 5-fold higher odds of having severe untreated dental problems (2 or more teeth with untreated caries) than White children. Adjustment for demographic, socioeconomic, and caries-related behavior variables attenuated but did not eliminate ethnic disparities in oral health, with the exception of Latin American children whose outcomes did not differ significantly from White populations after adjustment. Significant ethnic disparities in oral health exist in Alberta, Canada, even when adjusting for demographic, socioeconomic and caries-related behavioral factors, with Filipino, Arab, and Indigenous children being the most affected.

1 February 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
SBSean M. Bagshaw
Sean M. Bagshaw
XWXioaming Wang
Xioaming Wang
DZDavid A. Zygun
David A. Zygun
DZDan Zuege
Dan Zuege
PDPeter Dodek
Peter Dodek
HSHenry T. Stelfox
Henry T. Stelfox

1 October 2021 in Annals of Internal Medicine
Verified
Journal Article
Closed access
RSRobert Sheldon
Robert Sheldon
PFPeter Faris
Peter Faris
ATAnthony Tang
Anthony Tang
FAFelix Ayala-Paredes
Felix Ayala-Paredes
JGJuan Guzman
Juan Guzman
PIPOST 4 investigators
POST 4 investigators
Some patients with vasovagal syncope have frequent fainting episodes, which increases their risk for injury when they fall, when they are driving, or in other potentially dangerous situations. Mido... Visual Midodrine for the Prevention of Vasovagal Syncope. Some patients with vasovagal syncope have frequent fainting episodes, which increases their risk for injury when they fall, when t... Background: Recurrent vasovagal syncope is common, responds poorly to treatment, and causes physical trauma and poor quality of life. Midodrine prevents hypotension and syncope during tilt tests in...

2 August 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
GNGregg Nelson
Gregg Nelson
XWXiaoming Wang
Xiaoming Wang
ANAlison Nelson
Alison Nelson
PFPeter Faris
Peter Faris
LLLaura Lagendyk
Laura Lagendyk
LGLeah Gramlich
Leah Gramlich
Enhanced Recovery After Surgery (ERAS) is a global surgical quality improvement program that involves evidence-based guidelines and implementation strategies designed to improve patient outcomes by engaging multidisciplinary care teams in surgical practice change.1 An increasing body of evidence has demonstrated the effectiveness of systemwide implementation of ERAS in improving patient outcomes while achieving cost savings in colorectal surgery2-5 and other disciplines.6 Benefits include decreased hospital length of stay (LOS) and decreased complications, with no significant increase in readmission or mortality rates.1 Economic evaluation of ERAS has demonstrated its cost-effectiveness and supported expansion across surgical disciplines with return on investment ratios as high as 7.3.7

11 May 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
USUtkarsh B Subnis
Utkarsh B Subnis
NFNorman Farb
Norman Farb
KPKatherine-Ann Laura Piedalue
Katherine-Ann Laura Piedalue
MSMichael Speca
Michael Speca
SLSasha Lupichuk
Sasha Lupichuk
Linda CarlsonLinda Carlson
Linda Carlson
Background: Cancer patients transitioning to survivorship after completing cancer treatments need psychosocial interventions to manage stressors such as anxiety, depression, and fear of cancer recurrence. Mindfulness-based interventions (MBIs) are effective for treating these symptoms; however, cancer survivors are often unable to participate in face-to-face interventions because of difficulties such as work and family commitments, treatment-related side-effects, scheduling conflicts, and geography. Smartphone app–based MBIs are an innovative way to deliver psychosocial cancer care and can overcome several such difficulties, since patients can participate at their own convenience. Objective: The SEAMLESS (Smartphone App–Based Mindfulness Intervention for Cancer Survivors) study aims to evaluate the efficacy of a tailored app-based mindfulness intervention for cancer survivors (the Am Mindfulness-Based Cancer Survivorship—MBCS—Journey) for treating (1) symptoms of stress (primary outcome), as well as (2) fear of cancer recurrence, anxiety, depression, fatigue, and overall physical functioning (secondary outcomes). This is the first Canadian efficacy trial of a tailored mindfulness app intervention in cancer survivors. Methods: This is a randomized waitlist-controlled trial, which will evaluate the effectiveness of Am MBCS for impacting the primary and secondary outcomes in cancer survivors who have completed all their cancer treatments. Outcomes will be assessed using web-based surveys with validated psychometric instruments at (1) baseline, (2) mid-intervention (2 weeks later), (3) immediately postintervention (4 weeks), (4) 3 months postbaseline, (5) 6 months postbaseline, and (6) 12 months postbaseline. The waitlist group will complete all assessments and will cross over to the intervention condition after the 3-month assessment. In addition, data will be obtained by the smartphone app itself, which includes users’ engagement with the app-based intervention, their emotional state (eg, angry and elated) from a user-inputted digital emotion-mapping board, and psychobiometric data using photoplethysmography technology. Results: The study received ethics approval in September 2018 and recruitment commenced in January 2019. Participants are being recruited through a provincial cancer registry, and the majority of participants currently enrolled are breast (44/83, 53%) or colorectal (17/83, 20%) cancer survivors, although some survivors of other cancer are also present. Data collection for analysis of the primary outcome time-point will be complete by September 2019, and the follow-up data will be collected and analyzed by September 2020. Data will be analyzed to determine group differences using linear mixed modelling statistical techniques. Conclusions: Cancer care providers are uncertain about the efficacy of app-based mindfulness interventions for patients, which are available in great supply in today’s digital world. This study will provide rigorously evaluated efficacy data for an app-based mindfulness intervention for cancer survivors, which if helpful, could be made available for psychosocial care at cancer centers worldwide. Trial Registration: ClinicalTrials.gov NCT03484000; https://clinicaltrials.gov/ct2/show/NCT03484000 International Registered Report Identifier (IRRID): DERR1-10.2196/15178

16 May 2013 in Trials
Verified
Journal Article
Open access
PDF file
DRDerek J Roberts
Derek J Roberts
CJCraig Jenne
Craig Jenne
CBChad G. Ball
Chad G. Ball
CTCorina Tiruta
Corina Tiruta
CLCaroline Léger
Caroline Léger
AKAndrew Wallace Kirkpatrick
Andrew Wallace Kirkpatrick
Background: Damage control laparotomy, or abbreviated initial laparotomy followed by temporary abdominal closure (TAC), intensive care unit resuscitation, and planned re-laparotomy, is frequently used to manage intra-abdominal bleeding and contamination among critically ill or injured adults. Animal data suggest that TAC techniques that employ negative pressure to the peritoneal cavity may reduce the systemic inflammatory response and associated organ injury. The primary objective of this study is to determine if use of a TAC dressing that affords active negative pressure peritoneal therapy, the ABThera Open Abdomen Negative Pressure Therapy System, reduces the extent of the systemic inflammatory response after damage control laparotomy for intra-abdominal sepsis or injury as compared to a commonly used TAC method that provides potentially less efficient peritoneal negative pressure, the Barker’s vacuum pack.Methods/Design: The Intra-peritoneal Vacuum Trial will be a single-center, randomized controlled trial. Adults will be intraoperatively allocated to TAC with either the ABThera or Barker’s vacuum pack after the decision has been made by the attending surgeon to perform a damage control laparotomy. The study will use variable block size randomization. On study days 1, 2, 3, 7, and 28, blood will be collected. Whenever possible, peritoneal fluid will also be collected at these time points from the patient’s abdomen or TAC device. Luminex technology will be used to quantify the concentrations of 65 mediators relevant to the inflammatory response in peritoneal fluid and plasma. The primary endpoint is the difference in the plasma concentration of the pro-inflammatory cytokine IL-6 at 24 and 48 h after TAC dressing application. Secondary endpoints include the differential effects of these dressings on the systemic concentration of other pro-inflammatory cytokines, collective peritoneal and systemic inflammatory mediator profiles, postoperative fluid balance, intra-abdominal pressure, and several patient-important outcomes, including organ dysfunction measures and mortality.Discussion: Results from this study will improve understanding of the effect of active negative pressure peritoneal therapy after damage control laparotomy on the inflammatory response. It will also gather necessary pilot information needed to inform design of a multicenter trial comparing clinical outcomes among patients randomized to TAC with the ABTheraversusBarker’s vacuum pack.Trial registration: ClinicalTrials.gov identifierhttp://www.clicaltrials.gov/ct2/show/NCT01355094